Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 16/20 | 0.55 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.45 |
| ▸ | FPR2 | P25090 | 4/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3455931 | 0.86 | MAP2K1 (0.52) | MAP2K1MAP2K2FPR2 | |
| SCHEMBL3456059 | 0.84 | MAP2K1 (0.61) | MAP2K1MAP2K2 | |
| SCHEMBL28794321 | 0.83 | MAP2K1 (0.56) | MAP2K1MAP2K2FPR2 | |
| SCHEMBL1221822 | 0.81 | MAP2K1 (0.53) | MAP2K1MAP2K2 | |
| SCHEMBL393267 | 0.79 | MAP2K1 (0.60) | MAP2K1MAP2K2 | |
| SCHEMBL27659404 | 0.78 | MAP2K1 (0.58) | MAP2K1MAP2K2 | |
| SCHEMBL388540 | 0.77 | MAP2K1 (0.46) | MAP2K1MAP2K2 | |
| SCHEMBL388427 | 0.75 | MAP2K1 (0.74) | MAP2K1MAP2K2 | |
| SCHEMBL387684 | 0.75 | MAP2K1 (0.58) | MAP2K1MAP2K2 | |
| SCHEMBL1777798 | 0.74 | MAP2K1 (0.74) | MAP2K1MAP2K2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090209542-A1 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2009-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209542-A1 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | NRAS, BRAF, MAPK9 | MAP2K1 98/4885MAP2K2 82/4885FPR2 1339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.